uid	pubdate	authors	title	fulljournalname	elocationid
30594037	2018 Dec 26	Zhang W, Zhang J, Zhang Z, Guo Y, Wu Y, Wang R, Wang L, Mao S, Yao X	Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer.	Translational oncology	doi: 10.1016/j.tranon.2018.11.012
30593257	2018 Dec 28	Sun X, Liang L, Gu J, Zhuo W, Yan X, Xie T, Wu Z, Liu X, Gou X, Liu W, He G, Gan Y, Chang S, Shi H, Hu J	Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition, and binding free energy.	Journal of biomolecular structure &amp; dynamics	doi: 10.1080/07391102.2018.1563568
30592196	2018 Dec 28	Şahin S, Batur Ş, Aydın Ö, Öztürk T, Turna A, Öz B	PD-L1 Expression in Non Small Cell Lung Cancer and Prognosis	Balkan medical journal	doi: 10.4274/balkanmedj.2018.0392
30591531	2018 Dec 27	Tang H, Liu Y, Wang C, Zheng H, Chen Y, Liu W, Chen X, Zhang J, Chen H, Yang Y, Yang J	Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.	The Journal of pharmacology and experimental therapeutics	pii: jpet.118.254359. doi: 10.1124/jpet.118.254359
30591493	2019 Jan	Saito H, Shimizu S, Kono Y, Murakami Y, Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Ashida K, Fujiwara Y	PD-1 Expression on Circulating CD8&lt;sup&gt;+&lt;/sup&gt; T-Cells as a Prognostic Marker for Patients With Gastric Cancer.	Anticancer research	doi: 10.21873/anticanres.13132
30591423	2018 Dec 27	Tièche CC, Gao Y, Bührer ED, Hobi N, Berezowska SA, Wyler K, Froment L, Weis S, Peng RW, Bruggmann R, Schär P, Amrein MA, Hall SRR, Dorn P, Kocher G, Riether C, Ochsenbein A, Schmid RA, Marti TM	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549.	Neoplasia (New York, N.Y.)	doi: 10.1016/j.neo.2018.09.008
30591101	2018 Dec 20	Peng X, Zhou Q	[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	doi: 10.3779/j.issn.1009-3419.2018.12.11
30589949	2018 Dec 27	Gide TN, Allanson BM, Menzies AM, Ferguson PM, Madore J, Saw RPM, Thompson JF, Long GV, Wilmott JS, Scolyer RA	Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment.	Histopathology	doi: 10.1111/his.13814
30589920	2018 Dec 27	Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.	JAMA oncology	doi: 10.1001/jamaoncol.2018.5801
30589644	2018 Dec 27	Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.	The Journal of clinical investigation	pii: 123319. doi: 10.1172/JCI123319
30588196	2018	Yoshida S, Nagatsuka H, Nakano K, Kogashiwa Y, Ebihara Y, Yano M, Yasuda M	Significance of PD-L1 Expression in Tongue Cancer Development.	International journal of medical sciences	doi: 10.7150/ijms.27860
30587982	2019	Xu S, Cui F, Huang D, Zhang D, Zhu A, Sun X, Cao Y, Ding S, Wang Y, Gao E, Zhang F	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.	International journal of nanomedicine	doi: 10.2147/IJN.S175340
30587849	2018 Dec 27	Liu C, He H, Li X, Su MA, Cao Y	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.	British journal of cancer	doi: 10.1038/s41416-018-0363-8
30587623	2019 Jan-Feb	Doi H, Nakamatsu K, Anami S, Fukuda K, Inada M, Tatebe H, Ishikawa K, Kanamori S, Monzen H, Nishimura Y	Neutrophil-to-Lymphocyte Ratio Predicts Survival After Whole-brain Radiotherapy in Non-small Cell Lung Cancer.	In vivo (Athens, Greece)	doi: 10.21873/invivo.11459
30587556	2018 Dec 26	Principe DR, Park A, Dorman MJ, Kumar S, Viswakarma N, Rubin J, Torres C, McKinney R, Munshi HG, Grippo PJ, Rana A	TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer.	Molecular cancer therapeutics	pii: molcanther.0850.2018. doi: 10.1158/1535-7163.MCT-18-0850
30586539	2018 Oct	Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin Q, Pei L, Cai F, Ma L, Yu Y	The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.	Discovery medicine	
30584967	2018 Dec 22	Rui X, Gu TT, Pan HF, Zhang HZ	Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.	International immunopharmacology	doi: 10.1016/j.intimp.2018.12.018
30584711	2018 Dec 25	Yan Y, Zhao C, Yang R, Zhou T, Xu N	[IFN-γ induces overexpression of PD-L1 and epithelialmesenchymal transformation of breast cancer cells through activating ERK/Jak2-STAT signaling pathways].	Sheng wu gong cheng xue bao = Chinese journal of biotechnology	doi: 10.13345/j.cjb.180070
30584321	2018	Liu J, Zhong Y, Peng S, Zhou X, Gan X	Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.	OncoTargets and therapy	doi: 10.2147/OTT.S181413
30583461	2018 Dec 21	Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.	Cancers	pii: E11. doi: 10.3390/cancers11010011
30583235	2018 Dec 21	Kim JS, Kim B, Lee HK, Kim HS, Park EJ, Choi YJ, Ahn GB, Yun J, Hong JT, Kim Y, Han SB	Characterization of morphological changes of B16 melanoma cells under natural killer cell attack.	International immunopharmacology	doi: 10.1016/j.intimp.2018.12.037
30582788	2018 Dec 24	Yan M, Liu Y, Zhu X, Wang X, Liu L, Sun H, Wang C, Kong D, Ma G	Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity.	ACS applied materials &amp; interfaces	doi: 10.1021/acsami.8b18751
30582756	2018 Dec 24	Pawłowska A, Suszczyk D, Okła K, Barczyński B, Kotarski J, Wertel I	Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.	Clinical and experimental immunology	doi: 10.1111/cei.13255
30582397	2018 Dec 24	Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Roccuzzo G, Colella G, Caraglia M, Franco R	Oral and oropharyngeal squamous cell carcinoma: histopathological parameters of aggressive behavior.	Expert review of anticancer therapy	doi: 10.1080/14737140.2019.1561288
30582240	2018 Dec 23	Cao C, Wei Q, Tang X, Jia Y, Sun X, Li W, Hu Q, Chen X	PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: A substudy of a randomized phase III trial.	Head &amp; neck	doi: 10.1002/hed.25601
30580966	2018 Dec 14	Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L	Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.	Cell	pii: S0092-8674(18)31502-2. doi: 10.1016/j.cell.2018.11.010
30579680	2018 Dec 19	Jayaraj R, Kumarasamy C, Samiappan S, Swaminathan P	Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".	Oral oncology	pii: S1368-8375(18)30482-2. doi: 10.1016/j.oraloncology.2018.12.018
30579571	2018 Dec 19	Tétu P, Baroudjian B, Madelaine I, Delyon J, Lebbé C	[Update in treatment for Merkel Cell Carcinoma and clinical practice guide].	Bulletin du cancer	pii: S0007-4551(18)30365-5. doi: 10.1016/j.bulcan.2018.11.009
30579259	2018 Dec 14	Nicol AF, de Andrade CV, Gomes SC Jr, Brusadelli MG, Lodin HM, Wells SI, Nuovo GJ	The distribution of novel biomarkers in carcinoma-in-situ, microinvasive, and squamous cell carcinoma of the uterine cervix.	Annals of diagnostic pathology	doi: 10.1016/j.anndiagpath.2018.12.001
30578744	2018 Dec 22	Wang LL, Li ZH, Duan YG, Yuan SQ, Mor G, Liao AH	Identification of programmed cell death 1 and its ligand in the testicular tissue of mice.	American journal of reproductive immunology (New York, N.Y. : 1989)	doi: 10.1111/aji.13079
30577837	2018 Dec 22	Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.	Journal for immunotherapy of cancer	doi: 10.1186/s40425-018-0477-9
30577797	2018 Dec 21	Li Z, Song W, Rubinstein M, Liu D	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.	Journal of hematology &amp; oncology	doi: 10.1186/s13045-018-0684-3
30577587	2018 Dec 21	Wirsdörfer F, de Leve S, Jendrossek V	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?	International journal of molecular sciences	pii: E24. doi: 10.3390/ijms20010024
30577521	2018 Dec 20	Vrána D, Matzenauer M, Neoral Č, Aujeský R, Vrba R, Melichar B, Rušarová N, Bartoušková M, Jankowski J	From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.	International journal of molecular sciences	pii: E13. doi: 10.3390/ijms20010013
30576970	2018 Dec 18	Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2018.11.015
30576871	2018 Dec 18	Gupta S, Vanderbilt CM, Cotzia P, Arias Stella JA 3rd, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.	The Journal of molecular diagnostics : JMD	pii: S1525-1578(18)30244-7. doi: 10.1016/j.jmoldx.2018.10.006
30574431	2018	Yu W, Chen L, Guo S, Luo L, Chen L	B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells.	Oncoimmunology	doi: 10.1080/2162402X.2018.1504156
30574211	2018	Fabrizio FP, Trombetta D, Rossi A, Sparaneo A, Castellana S, Muscarella LA	Gene code &lt;i&gt;CD274/PD-L1&lt;/i&gt;: from molecular basis toward cancer immunotherapy.	Therapeutic advances in medical oncology	doi: 10.1177/1758835918815598
30571927	2018 Dec 20	Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, Hancock JF, Poklepovic A, Dent P	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα&lt;sub&gt;q&lt;/sub&gt; and Gα&lt;sub&gt;11&lt;/sub&gt; and kill uveal melanoma cells.	Cancer biology &amp; therapy	doi: 10.1080/15384047.2018.1551747
30570649	2018 Dec 20	Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.	JAMA oncology	doi: 10.1001/jamaoncol.2018.5441
30569516	2018 Dec 20	Traini G, Ruiz-de-Angulo A, Blanco-Canosa JB, Zamacola Bascarán K, Molinaro A, Silipo A, Escors D, Mareque-Rivas JC	Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.	Small (Weinheim an der Bergstrasse, Germany)	doi: 10.1002/smll.201803993
30569297	2018 Dec 19	Yomoda T, Sudo T, Kawahara A, Shigaki T, Shimomura S, Tajiri K, Nagasu S, Fujita F, Kinugasa T, Akagi Y	The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.	Annals of surgical oncology	doi: 10.1245/s10434-018-07110-z
30568661	2018	Bazhin AV, Amedei A, Karakhanova S	Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.	Frontiers in immunology	doi: 10.3389/fimmu.2018.02878
30568505	2018	Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS, Xia JC	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma.	Cancer management and research	doi: 10.2147/CMAR.S181949
30568128	2018 Dec 18	Naito M, Tamiya A, Takeda M, Taniguchi Y, Saijo N, Naoki Y, Okishio K, Yoon H, Kasai T, Matsumura A, Atagi S	A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.	Internal medicine (Tokyo, Japan)	doi: 10.2169/internalmedicine.1462-18
30568113	2018 Dec 18	Senoo S, Ninomiya T, Makimoto G, Nishii K, Kano H, Watanabe H, Hata Y, Kubo T, Tanaka T, Hotta K, Maeda Y, Kiura K	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab: A Case Report.	Internal medicine (Tokyo, Japan)	doi: 10.2169/internalmedicine.0890-18
30567732	2018 Dec 19	Peng C, Hu Q, Yang F, Zhang H, Li F, Huang C	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	Journal of immunology (Baltimore, Md. : 1950)	pii: ji1800876. doi: 10.4049/jimmunol.1800876
30566947	2018 Dec 19	Pisapia P, Malapelle U, Troncone G	Liquid Biopsy and Lung Cancer.	Acta cytologica	doi: 10.1159/000492710
30565869	2018 Dec	Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, Kenny L, O'Byrne K, Punyadeera C	The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.	Cancer medicine	doi: 10.1002/cam4.1832
30565707	2018 Dec 19	Gu W, Wang L, Wu Y, Liu JP	Undo the brake of tumour immune tolerance with antibodies, peptides and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells.	Clinical and experimental pharmacology &amp; physiology	doi: 10.1111/1440-1681.13056
30565657	2018 Nov 22	Zhu S, Lv X, Zhang X, Li T, Zang G, Yang N, Wang X, Wu J, Chen W, Liu YJ, Chen J	An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.	International journal of cancer	doi: 10.1002/ijc.32008
30565573	2018 Nov	Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Banna GL	[Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?]	Recenti progressi in medicina	doi: 10.1701/3031.30291
30565086	2018 Dec 18	González Del Alba A, De Velasco G, Lainez N, Maroto P, Morales-Barrera R, Muñoz-Langa J, Pérez-Valderrama B, Basterretxea L, Caballero C, Vazquez S	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).	Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	doi: 10.1007/s12094-018-02001-x
30565045	2018 Dec 18	Shigemori T, Toiyama Y, Okugawa Y, Yamamoto A, Yin C, Narumi A, Ichikawa T, Ide S, Shimura T, Fujikawa H, Yasuda H, Hiro J, Yoshiyama S, Ohi M, Araki T, Kusunoki M	Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.	Annals of surgical oncology	doi: 10.1245/s10434-018-07112-x
30565043	2018 Dec 18	Zheng X, Dong L, Wang K, Zou H, Zhao S, Wang Y, Wang G	MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.	Annals of surgical oncology	doi: 10.1245/s10434-018-07117-6
30564891	2018 Dec 18	Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2282-1
30564890	2018 Dec 18	Hassounah NB, Malladi VS, Huang Y, Freeman SS, Beauchamp EM, Koyama S, Souders N, Martin S, Dranoff G, Wong KK, Pedamallu CS, Hammerman PS, Akbay EA	Identification and characterization of an alternative cancer-derived PD-L1 splice variant.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2284-z
30564889	2018 Dec 18	Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R	Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2285-y
30564631	2018	Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.	NPJ breast cancer	doi: 10.1038/s41523-018-0095-1
30564277	2018	Liang L, Ge K, Zhang F, Ge Y	The suppressive effect of co-inhibiting &lt;i&gt;PD-1&lt;/i&gt; and &lt;i&gt;CTLA-4&lt;/i&gt; expression on H22 hepatomas in mice.	Cellular &amp; molecular biology letters	doi: 10.1186/s11658-018-0122-0
30563829	2018 Dec 18	Svatek RS, Ji N, de Leon EMB, Mukherjee N, Kabra A, Hurez V, Nicolas M, Michalek JE, Javors M, Wheeler K, Sharp ZD, Livi CB, Shu ZJ, Henkes DN, Curiel TJ	Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer.	Cancer immunology research	pii: canimm.0336.2018. doi: 10.1158/2326-6066.CIR-18-0336
30563828	2018 Dec 18	Polesso F, Weinberg A, Moran AE	Late stage tumor regression after PD-L1 blockade with a concurrent OX40 agonist.	Cancer immunology research	pii: canimm.0222.2018. doi: 10.1158/2326-6066.CIR-18-0222
30563569	2018 Dec 18	Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang Y, Zhao J, Chen Y, Zhang T, Huang F, Pan N, Zhang J, Fox BA, Hu HM, Wang LX	Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.	Journal for immunotherapy of cancer	doi: 10.1186/s40425-018-0452-5
30563566	2018 Dec 18	Fromm G, de Silva S, Johannes K, Patel A, Hornblower JC, Schreiber TH	Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.	Journal for immunotherapy of cancer	doi: 10.1186/s40425-018-0454-3
30563160	2018 Dec 5	Kim K, Jeon S, Kim TM, Jung CK	Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes.	Cancers	pii: E494. doi: 10.3390/cancers10120494
30563098	2018 Dec 5	Stepanenko AA, Chekhonin VP	Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?	Cancers	pii: E492. doi: 10.3390/cancers10120492
30562859	2017 Feb	Fuse M, Yoshimura K	The development status of the next-generation immune checkpoint inhibitors.	Nihon rinsho. Japanese journal of clinical medicine	
30561439	2015 Apr 30	ghavan D	Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years.	Bladder cancer (Amsterdam, Netherlands)	doi: 10.3233/BLC-150010
30562710	2018 Dec 15	von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K	Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2018.11.020
30561902	2018 Dec 18	Nishihira M, Nakazato Y, Maeda S, Inoue T, Araki O, Karube Y, Chida M	Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma.	Thoracic cancer	doi: 10.1111/1759-7714.12935
30561383	2018 Dec 18	Valentinuzzi D, Simoncic U, Ursic K, Vrankar M, Turk M, Jeraj R	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling.	Physics in medicine and biology	doi: 10.1088/1361-6560/aaf96c
30559926	2018 Nov 23	Trivedi P, Slack FJ, Anastasiadou E	Epstein-Barr virus: From kisses to cancer, an ingenious immune evader.	Oncotarget	doi: 10.18632/oncotarget.26381
30559738	2018	Raftery MJ, Abdelaziz MO, Hofmann J, Schönrich G	Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.	Frontiers in immunology	doi: 10.3389/fimmu.2018.02560
30559623	2018 Winter	Kabir TF, Chauhan A, Anthony L, Hildebrandt GC	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018.	The Ochsner journal	doi: 10.31486/toj.18.0055
30557521	2018 Dec 13	Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	doi: 10.1200/JCO.2018.78.2276
30556751	2018 Dec 17	Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Yousefi M, Jadidi-Niaragh F	CD73 as a potential opportunity for cancer immunotherapy.	Expert opinion on therapeutic targets	doi: 10.1080/14728222.2019.1559829
30555574	2018	Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, Liu LZ, Shi JY, Yang LX, Wang ZC, Zhang S, Ding ZB, Ke AW, Cao Y, Zhang XM, Zhou J, Fan J, Wang XY, Gao Q	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma.	Theranostics	doi: 10.7150/thno.28742
30555473	2018	Machicote A, Belén S, Baz P, Billordo LA, Fainboim L	Human CD8&lt;sup&gt;+&lt;/sup&gt;HLA-DR&lt;sup&gt;+&lt;/sup&gt; Regulatory T Cells, Similarly to Classical CD4&lt;sup&gt;+&lt;/sup&gt;Foxp3&lt;sup&gt;+&lt;/sup&gt; Cells, Suppress Immune Responses via PD-1/PD-L1 Axis.	Frontiers in immunology	doi: 10.3389/fimmu.2018.02788
30555157	2018 Dec 17	Ma H, Yang W, Zhang L, Liu S, Zhao M, Zhou G, Wang L, Jin S, Zhang Z, Hu J	Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.	British journal of cancer	doi: 10.1038/s41416-018-0352-y
30553600	2018 Nov 22	Malm IJ, Rooper LM, Bishop JA, Ozgursoy SK, Hillel AT, Akst LM, Best SR	Molecular and immunologic analysis of laryngeal squamous cell carcinoma in smokers and non-smokers.	American journal of otolaryngology	pii: S0196-0709(18)30882-2. doi: 10.1016/j.amjoto.2018.11.009
30552520	2018 Dec 14	Mandalà M, Rutkowski P	Rational combination of cancer immunotherapy in melanoma.	Virchows Archiv : an international journal of pathology	doi: 10.1007/s00428-018-2506-y
30552459	2018 Dec 14	Lin L, Rayman P, Pavicic PG Jr, Tannenbaum C, Hamilton T, Montero A, Ko J, Gastman B, Finke J, Ernstoff M, Diaz-Montero CM	Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8&lt;sup&gt;+&lt;/sup&gt; T cells from negative regulation by local IFN-γ.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2280-3
30552160	2018 Dec 14	Nishijima TF, Shachar SS, Muss HB, Tamura K	Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.	The oncologist	pii: theoncologist.2018-0449. doi: 10.1634/theoncologist.2018-0449
30552042	2018 Dec 6	Zou J, Wu D, Li T, Wang X, Liu Y, Tan S	Association of PD-L1 gene rs4143815 C&amp;gt;G polymorphism and human cancer susceptibility: A systematic review and meta-analysis.	Pathology, research and practice	pii: S0344-0338(18)31300-1. doi: 10.1016/j.prp.2018.12.002
30552022	2018 Dec 18	Nakanishi Y, Duran A, L'Hermitte A, Shelton PM, Nakanishi N, Reina-Campos M, Huang J, Soldevila F, Baaten BJG, Tauriello DVF, Castilla EA, Bhangoo MS, Bao F, Sigal D, Diaz-Meco MT, Moscat J	Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance.	Immunity	doi: 10.1016/j.immuni.2018.09.013
30550791	2018 Dec 13	Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ	Organoid Modeling of the Tumor Immune Microenvironment.	Cell	doi: 10.1016/j.cell.2018.11.021
30549362	2018 Dec 14	Cioni B, Jordanova ES, Hooijberg E, van der Linden R, de Menezes RX, Tan K, Willems S, Elbers JBW, Broeks A, Bergman AM, Zuur CL, de Boer JP	HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.	Head &amp; neck	doi: 10.1002/hed.25442
30548363	2018 Dec 12	Wang B, Pan W, Yang M, Yang W, He W, Chen X, Bi J, Jiang N, Huang J, Lin T	Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.	Cancer science	doi: 10.1111/cas.13887
30548240	2018 Dec 11	Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	Cancer	doi: 10.1002/cncr.31871
30547271	2018 Dec 13	Manson QF, Schrijver WAME, Ter Hoeve ND, Moelans CB, van Diest PJ	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.	Clinical &amp; experimental metastasis	doi: 10.1007/s10585-018-9950-6
30547224	2018 Dec 13	d'Hargues Y, Prinz J, Gödel P, Shimabukuro-Vornhagen A, Kochanek M, Böll B	[Diagnosis and treatment of immune-related adverse events during checkpoint inhibitor therapy in intensive care medicine].	Medizinische Klinik, Intensivmedizin und Notfallmedizin	doi: 10.1007/s00063-018-0521-z
30547218	2018 Dec 13	Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2283-0
30547012	2018	Yang B, Liu T, Qu Y, Liu H, Zheng SG, Cheng B, Sun J	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.	Frontiers in oncology	doi: 10.3389/fonc.2018.00563
30546958	2019	Walkowska J, Kallemose T, Jönsson G, Jönsson M, Andersen O, Andersen MH, Svane IM, Langkilde A, Nilbert M, Therkildsen C	Immunoprofiles of colorectal cancer from Lynch syndrome.	Oncoimmunology	doi: 10.1080/2162402X.2018.1515612
30546955	2019	Kang SH, Keam B, Ahn YO, Park HR, Kim M, Kim TM, Kim DW, Heo DS	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.	Oncoimmunology	doi: 10.1080/2162402X.2018.1515057
30546953	2019	Varn FS, Wang Y, Cheng C	A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy.	Oncoimmunology	doi: 10.1080/2162402X.2018.1513440
30546952	2019	Proctor DT, Patel Z, Lama S, Resch L, van Marle G, Sutherland GR	Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.	Oncoimmunology	doi: 10.1080/2162402X.2018.1512943
30546949	2019	Yue P, Harper T, Bacot SM, Chowdhury M, Lee S, Akue A, Kukuruga MA, Wang T, Feldman GM	BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways.	Oncoimmunology	doi: 10.1080/2162402X.2018.1512456
30546089	2018 Dec 13	Li L, Cao B, Liang X, Lu S, Luo H, Wang Z, Wang S, Jiang J, Lang J, Zhu G	Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes.	Oncogene	doi: 10.1038/s41388-018-0627-z
30546030	2018 Dec 13	Sampedro-Núñez M, Serrano-Somavilla A, Adrados M, Cameselle-Teijeiro JM, Blanco-Carrera C, Cabezas-Agricola JM, Martínez-Hernández R, Martín-Pérez E, Muñoz de Nova JL, Díaz JÁ, García-Centeno R, Caneiro-Gómez J, Abdulkader I, González-Amaro R, Marazuela M	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.	Scientific reports	doi: 10.1038/s41598-018-36129-1
30546008	2018 Dec 13	Darvin P, Toor SM, Sasidharan Nair V, Elkord E	Immune checkpoint inhibitors: recent progress and potential biomarkers.	Experimental &amp; molecular medicine	doi: 10.1038/s12276-018-0191-1
30544743	2018 Dec 10	Roussille P, Tachon G, Villalva C, Milin S, Frouin E, Godet J, Berger A, Emambux S, Petropoulos C, Wager M, Karayan-Tapon L, Tougeron D	Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases.	Cancers	pii: E504. doi: 10.3390/cancers10120504
30544524	2018 Dec 7	Hsu PC, Yang CT, Jablons DM, You L	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.	Biomedicines	pii: E114. doi: 10.3390/biomedicines6040114
30544444	2018 Dec	Caruso ML, Di Pinto F, Ignazzi A, Coletta S, Valentini AM, Cavalcanti E, De Michele F	Increased nerve twigs in small intestinal mucosa with programmed cell death-ligand 1 and somatostatin receptor type 2A expression in recurrent Crohn disease: A case report.	Medicine	doi: 10.1097/MD.0000000000013492
30543161	2018 Dec 12	Brenowitz M, Chapman JR, Ueberheide B, Khine M, Pegan J, Law M, Makkaoui ME, Leser M	Chemical Generation of Hydroxyl Radical for Oxidative 'Footprinting'.	Protein and peptide letters	doi: 10.2174/0929866526666181212164812
30542345	2018	Brunner-Weinzierl MC, Rudd CE	CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.	Frontiers in immunology	doi: 10.3389/fimmu.2018.02737
30542036	2018	Sazuka M, Murano Y, Takada K, Nonaka K, Yamada H, Yamamoto H	[An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function].	Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics	doi: 10.3143/geriatrics.55.679
30541986	2018	Komohara Y, Noyori O, Saito Y, Takeya H, Baghdadi M, Kitagawa F, Hama N, Ishikawa K, Okuno Y, Nosaka K, Seino KI, Matsuoka M, Suzu S	Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.	Journal of clinical and experimental hematopathology : JCEH	doi: 10.3960/jslrt.18034
30541848	2018 Dec 12	Garcia-Bates TM, Palma ML, Shen C, Gambotto A, Macatangay BJC, Ferris RL, Rinaldo CR, Mailliard RB	Contrasting roles of the PD-1 signaling pathway in dendritic cell-mediated induction and regulation of HIV-1-specific effector T cell functions.	Journal of virology	pii: JVI.02035-18. doi: 10.1128/JVI.02035-18
30541787	2018 Dec 12	Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.	Science translational medicine	pii: eaau0417. doi: 10.1126/scitranslmed.aau0417
30541755	2018 Dec 12	Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt AW, Sartor O	Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.	The oncologist	pii: theoncologist.2018-0546. doi: 10.1634/theoncologist.2018-0546
30541754	2018 Dec 12	Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, Ibrahim A, McKee AE, Pazdur R, Beaver JA	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.	The oncologist	pii: theoncologist.2018-0084. doi: 10.1634/theoncologist.2018-0084
30541627	2018 Dec 12	Adam LC, Raja J, Ludwig JM, Adeniran A, Gettinger SN, Kim HS	Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.	Journal for immunotherapy of cancer	doi: 10.1186/s40425-018-0468-x
30541416	2018 Dec 12	Finlay WJJ, Coleman JE, Edwards JS, Johnson KS	Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.	mAbs	doi: 10.1080/19420862.2018.1550321
30524909	2018	Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Győrffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.	Oncoimmunology	doi: 10.1080/2162402X.2018.1526613
30524905	2018	Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, &lt;i&gt;BRCA1&lt;/i&gt;-like status, tumor-infiltrating immune cells and survival.	Oncoimmunology	doi: 10.1080/2162402X.2018.1509820
30524900	2018	Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.	Oncoimmunology	doi: 10.1080/2162402X.2018.1502905
30524885	2018	McEachron TA, Triche TJ, Sorenson L, Parham DM, Carpten JD	Profiling targetable immune checkpoints in osteosarcoma.	Oncoimmunology	doi: 10.1080/2162402X.2018.1475873
30524881	2018	George S, Papanicolau-Sengos A, Lenzo FL, Conroy JM, Nesline M, Pabla S, Glenn ST, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Galluzzi L, Morrison C	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.	Oncoimmunology	doi: 10.1080/2162402X.2018.1460298
30524879	2018	Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.	Oncoimmunology	doi: 10.1080/2162402X.2017.1405206
30524878	2018	Huang Q, Zhang H, Hai J, Socinski MA, Lim E, Chen H, Stebbing J	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.	Oncoimmunology	doi: 10.1080/2162402X.2017.1396403
30523626	2019	Goldstein RH, DeCaprio JA	Merkel Cell Carcinoma in the HIV-1/AIDS Patient.	Cancer treatment and research	doi: 10.1007/978-3-030-03502-0_8
30523370	2018 Dec 6	Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F	CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2281-2
30523049	2018 Dec 6	Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R	Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients.	Molecular cancer therapeutics	pii: molcanther.0535.2018. doi: 10.1158/1535-7163.MCT-18-0535
30523022	2018 Dec 6	Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN	Molecular subtype not immune response drives outcomes in endometrial carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	pii: clincanres.3241.2018. doi: 10.1158/1078-0432.CCR-18-3241
30522901	2018 Nov 13	Hong B, Cai L, Wang J, Liu S, Zhou J, Ma K, Zhang J, Zhou B, Peng X, Zhang N, Gong K	Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.	Clinical genitourinary cancer	pii: S1558-7673(18)30272-6. doi: 10.1016/j.clgc.2018.11.001
30522188	2018 Dec 8	Wang XR, Jia Y, Liu YP	[Research progrss on resistance of PD1/PD-L1 signal pathway].	Zhonghua bing li xue za zhi = Chinese journal of pathology	doi: 10.3760/cma.j.issn.0529-5807.2018.12.021
30540571	2018 Dec 11	Sarkozy C, Copie-Bergmand C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.	The American journal of surgical pathology	doi: 10.1097/PAS.0000000000001198
30539869	2018 Dec	Long J, Qu T, Pan XF, Tang X, Wan HH, Qiu P, Xu YH	Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.	Journal of cancer research and therapeutics	doi: 10.4103/0973-1482.204850
30539847	2018 Dec	Tawadros AIF, Khalafalla MMM	Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.	Journal of cancer research and therapeutics	doi: 10.4103/0973-1482.202891
30539796	2018 Dec	Devereaux KA, Charu V, Zhao S, Charville GW, Bangs CD, van de Rijn M, Cherry AM, Natkunam Y	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.	Human pathology	doi: 10.1016/j.humpath.2018.06.034
30539728	2018 Dec	Cabezas-Camarero S, Puebla F, Subhi-Issa AI, Sanz-Ortega J, Pérez-Segura P	Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer.	Oral oncology	doi: 10.1016/j.oraloncology.2018.10.019
30539511	2018	Tian Y, Abu-Sbeih H, Wang Y	Immune Checkpoint Inhibitors-Induced Hepatitis.	Advances in experimental medicine and biology	doi: 10.1007/978-3-030-02505-2_8
30539507	2018	Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N	Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.	Advances in experimental medicine and biology	doi: 10.1007/978-3-030-02505-2_4
30539506	2018	Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.	Advances in experimental medicine and biology	doi: 10.1007/978-3-030-02505-2_3
30539505	2018	Glitza Oliva IC, Alqusairi R	Immunotherapy for Melanoma.	Advances in experimental medicine and biology	doi: 10.1007/978-3-030-02505-2_2
30539504	2018	Stephen B, Hajjar J	Overview of Basic Immunology and Translational Relevance for Clinical Investigators.	Advances in experimental medicine and biology	doi: 10.1007/978-3-030-02505-2_1
30538704	2018	Oliva S, Troia R, D'Agostino M, Boccadoro M, Gay F	Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.	Frontiers in immunology	doi: 10.3389/fimmu.2018.02749
30538492	2018	Sun J, Jiang W, Tian D, Guo Q, Shen Z	Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression.	OncoTargets and therapy	doi: 10.2147/OTT.S179844
30538110	2018 Dec 11	Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter D, Ekmekcioglu S, Grimm EA	The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	pii: clincanres.1163.2018. doi: 10.1158/1078-0432.CCR-18-1163
30537988	2018 Dec 11	Deng R, Zhang P, Liu W, Zeng X, Ma X, Shi L, Wang T, Yin Y, Chang W, Zhang P, Wang G, Tao K	HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.	Clinical epigenetics	doi: 10.1186/s13148-018-0589-6
30537506	2018 Dec 10	Van den Eynde M, Mlecnik B, Bindea G, Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F, Angelova M, Vasaturo A, Bruni D, Jouret-Mourin A, Baldin P, Huyghe N, Haustermans K, Debucquoy A, Van Cutsem E, Gigot JF, Hubert C, Kartheuser A, Remue C, Léonard D, Valge-Archer V, Pagès F, Machiels JP, Galon J	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.	Cancer cell	doi: 10.1016/j.ccell.2018.11.003
30537493	2018 Dec 8	Zhai J, Giannini G, Ewalt MD, Zhang EY, Invernizzi M, Niland J, Lai LL	Molecular characterization of metaplastic breast carcinoma via next generation sequencing.	Human pathology	pii: S0046-8177(18)30477-5. doi: 10.1016/j.humpath.2018.11.023
30537444	2019 Jan	Manca P, Raez LE, Salzberg M, Sanchez J, Hunis B, Rolfo C	The value of immunotherapy in head and neck cancer.	Expert opinion on biological therapy	doi: 10.1080/14712598.2019.1556637
30537104	2018 Dec 11	Mo RJ, Han ZD, Liang YK, Ye JH, Wu SL, Lin SX, Zhang YQ, Song SD, Jiang FN, Zhong WD, Wu CL	Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8&lt;sup&gt;+&lt;/sup&gt; tumor-associated lymphocytes and poor prognosis in prostate cancer.	International journal of cancer	doi: 10.1002/ijc.32061
30536734	2018 Dec 11	Li W, Song P, Guo L, Liu X, Guo C, Ying J, Gao S	Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.	Thoracic cancer	doi: 10.1111/1759-7714.12929
30536665	2018 Dec 10	Ryu HJ, Kim EK, Cho BC, Yoon SO	Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity.	Head &amp; neck	doi: 10.1002/hed.25507
30536016	2018 Dec 11	Ehlerding EB, Lan X, Cai W	Predicting PD-1/PD-L1 status in bladder cancer with &lt;sup&gt;18&lt;/sup&gt;F-FDG PET?	European journal of nuclear medicine and molecular imaging	doi: 10.1007/s00259-018-4224-8
30534975	2018 Dec 6	Hernandez A, Brandler TC, Zhou F, Moreira AL, Schatz-Siemers N, Simsir A	Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma: A Comparative Study With Paired Surgical Specimens.	American journal of clinical pathology	doi: 10.1093/ajcp/aqy164
30534602	2018	Abedalthagafi M, Barakeh D, Foshay KM	Immunogenetics of glioblastoma: the future of personalized patient management.	NPJ precision oncology	doi: 10.1038/s41698-018-0070-1
30534571	2018	Qian C, Guo H, Chen X, Shi A, Li S, Wang X, Pan J, Fang C	Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility.	Journal of diabetes research	doi: 10.1155/2018/1614683
30534022	2018 Nov-Dec	Orbegoso C, Murali K, Banerjee S	The current status of immunotherapy for cervical cancer.	Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology	doi: 10.1016/j.rpor.2018.05.001
30529597	2018 Dec 4	Yang JC, Gadgeel SM, Sequist LVD, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A	Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	pii: S1556-0864(18)33506-8. doi: 10.1016/j.jtho.2018.11.028
30528981	2018 Oct 21	Kaczmarek M, Banaszewski J, Leszczyńska M, Łagiedo-Żelazowska M, Nowicka A, Romańska A, Wierzbicka M, Dworacki G	High frequency of macrophages expressing elevated level of CD80, PD-Ls and TLR1 in nasal polyps of CRS patients.	Immunobiology	pii: S0171-2985(18)30131-1. doi: 10.1016/j.imbio.2018.09.004
30528808	2019 Jan	Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2018.11.007
30528799	2019 Jan	Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2018.11.002
30528699	2018 Dec 6	Criss SD, Weaver DT, Sheehan DF, Lee RJ, Pandharipande PV, Kong CY	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.	Urologic oncology	pii: S1078-1439(18)30464-2. doi: 10.1016/j.urolonc.2018.11.016
30528536	2018 Nov 22	Liang J, Hänsch GM, Hübner K, Samstag Y	Sulforaphane as anticancer agent: A double-edged sword? Tricky balance between effects on tumor cells and immune cells.	Advances in biological regulation	pii: S2212-4926(18)30156-8. doi: 10.1016/j.jbior.2018.11.006
30528265	2018 Dec 4	Li J, Yu T, Yan M, Zhang X, Liao L, Zhu M, Lin H, Pan H, Yao M	DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.	Experimental cell research	pii: S0014-4827(18)30682-7. doi: 10.1016/j.yexcr.2018.12.001
30528137	2018 Dec 4	Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.	The Lancet. Haematology	pii: S2352-3026(18)30175-3. doi: 10.1016/S2352-3026(18)30175-3
30528043	2018 Oct 21	Bi Y, Ren X, Bai X, Meng Y, Luo Y, Cao J, Zhang Y, Liang Z	PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.	European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology	pii: S0748-7983(18)31463-X. doi: 10.1016/j.ejso.2018.10.060
30527665	2018 Dec 3	Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.	Molecular cell	pii: S1097-2765(18)30894-3. doi: 10.1016/j.molcel.2018.10.034
30527224	2018 Dec	Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M, Swiss Group of Clinical Cancer Research (SAKK).	Cost-effectiveness of nivolumab in the treatment of head and neck cancer.	Oral oncology	doi: 10.1016/j.oraloncology.2018.10.032
30527198	2018 Dec	Capizzi E, Ricci C, Giunchi F, Zagnoni S, Ceccarelli C, Gómez BUÁ, Casolari L, Gelsomino F, Trisolini R, Fiorentino M, Ardizzoni A	Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	doi: 10.1016/j.lungcan.2018.10.017
30522700	2018 Dec 3	Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D	Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.	Gynecologic oncology	pii: S0090-8258(18)31418-5. doi: 10.1016/j.ygyno.2018.11.017
30522017	2018 Dec 3	Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI	PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.	Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie	doi: 10.1016/j.biopha.2018.11.105
30521746	2018 Dec 6	Nam S, Lee A, Lim J, Lim JS	Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs).	Biomolecules &amp; therapeutics	doi: 10.4062/biomolther.2018.201
30521597	2018	Ho KH, Chang CJ, Huang TW, Shih CM, Liu AJ, Chen PH, Cheng KT, Chen KC	Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.	PloS one	doi: 10.1371/journal.pone.0208459
30520757	2019 Feb	Fasching PA, Schneeweiss A, Kolberg HC, Ettl J, Fehm TN, Overkamp F, Lüftner D	Translational highlights in breast cancer research and treatment: recent developments with clinical impact.	Current opinion in obstetrics &amp; gynecology	doi: 10.1097/GCO.0000000000000510
30520029	2018 Nov 22	Farhood B, Najafi M, Mortezaee K	CD8&lt;sup&gt;+&lt;/sup&gt; cytotoxic T lymphocytes in cancer immunotherapy: A review.	Journal of cellular physiology	doi: 10.1002/jcp.27782
30519815	2018 Dec	Manson QF, Ter Hoeve ND, Buerger H, Moelans CB, van Diest PJ	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.	Targeted oncology	doi: 10.1007/s11523-018-0610-1
30519541	2018	Lin W, Chen M, Hong L, Zhao H, Chen Q	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.	Frontiers in oncology	doi: 10.3389/fonc.2018.00532
30519393	2018	Zheng R, Wang D, Wang K, Gao WX, Yang QT, Jiang LJ, Zhou M, Cao YJ, Shi J, Sun Y	Elevated expression of IL-17RB and ST2 on myeloid dendritic cells is associated with a Th2-skewed eosinophilic inflammation in nasal polyps.	Clinical and translational allergy	doi: 10.1186/s13601-018-0237-4
30519342	2018	Zhang X, Shi X, Li J, Mo L, Hu Z, Gao J, Wu S, Long Z	PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine.	Journal of Cancer	doi: 10.7150/jca.25423
30519336	2018	Wei XL, Wu QN, Chen DL, Zeng ZL, Lu JB, Liu ZX, Ju HQ, Ren C, Pan ZZ, Wang FH, Xu RH	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.	Journal of Cancer	doi: 10.7150/jca.27735
30519309	2018	Yao JX, Chen X, Xi W, Zhu YJ, Wang H, Hu XY, Guo JM	Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.	Journal of Cancer	doi: 10.7150/jca.27408
30519101	2018	Diem S, Fässler M, Ali OH, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.	Cancer management and research	doi: 10.2147/CMAR.S179767
30518877	2018 Dec 5	Grabosch S, Bulatovic M, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Fang Y, Tseng G, Kim E, Gambotto A, Elishaev E, P Edwards R, Vlad AM	Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.	Oncogene	doi: 10.1038/s41388-018-0581-9
30518694	2018 Dec 6	Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F	Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.	JCI insight	pii: 124507. doi: 10.1172/jci.insight.124507
30518409	2018 Dec 5	Bantia S, Choradia N	Treatment duration with immune-based therapies in Cancer: an enigma.	Journal for immunotherapy of cancer	doi: 10.1186/s40425-018-0465-0
30508306	2018 Dec 3	Huang J, Mo H, Zhang W, Chen X, Qu D, Wang X, Wu D, Wang X, Lan B, Yang B, Wang P, Zhang B, Yang Q, Jiao Y, Xu B	Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.	Cancer	doi: 10.1002/cncr.31855
30506500	2018 Dec 1	Grauer O, Jaber M, Hess K, Weckesser M, Schwindt W, Maring S, Wölfer J, Stummer W	Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.	Journal of neuro-oncology	doi: 10.1007/s11060-018-03005-x
30506460	2018 Dec 1	Chang B, Huang T, Wei H, Shen L, Zhu D, He W, Chen Q, Zhang H, Li Y, Huang R, Li W, Wu P	The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-018-2271-4
30506459	2018 Dec 1	Marchand L, Reffet S, Dalle S, Disse E, Vouillarmet J, Cugnet-Anceau C, Thivolet C	Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?	Acta diabetologica	doi: 10.1007/s00592-018-1262-4
30506221	2018 Nov 30	Du Y, Jin Y, Sun W, Fang J, Zheng J, Tian J	Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect.	European radiology	doi: 10.1007/s00330-018-5814-3
30505716	2018 Dec	Penault-Llorca F, Radosevic-Robin N	Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.	Translational lung cancer research	doi: 10.21037/tlcr.2018.09.26
30505713	2018 Dec	Evans M, O'Sullivan B, Smith M, Taniere P	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?	Translational lung cancer research	doi: 10.21037/tlcr.2018.06.09
30505712	2018 Dec	Truesdell J, Miller VA, Fabrizio D	Approach to evaluating tumor mutational burden in routine clinical practice.	Translational lung cancer research	doi: 10.21037/tlcr.2018.10.10
30505709	2018 Dec	Hendriks LE, Rouleau E, Besse B	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.	Translational lung cancer research	doi: 10.21037/tlcr.2018.09.22
30505708	2018 Dec	Greillier L, Tomasini P, Barlesi F	The clinical utility of tumor mutational burden in non-small cell lung cancer.	Translational lung cancer research	doi: 10.21037/tlcr.2018.10.08
30505707	2018 Dec	Heeke S, Hofman P	Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?	Translational lung cancer research	doi: 10.21037/tlcr.2018.08.04
30505679	2019	Uchida N, Fujita K, Okamura M, Nakatani K, Mio T	The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ∼experience of single public hospital in Japan∼.	Respiratory medicine case reports	doi: 10.1016/j.rmcr.2018.11.007
30505301	2018	Jelinek T, Paiva B, Hajek R	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.	Frontiers in immunology	doi: 10.3389/fimmu.2018.02431
30504406	2018 Dec	Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.	Anticancer research	doi: 10.21873/anticanres.13065
30504313	2018 Nov 30	rrera AF	Where does PD-1 blockade fit in HL therapy?	Hematology. American Society of Hematology. Education Program	doi: 10.1182/asheducation-2018.1.213
30516854	2018 Dec 5	Lang T, Liu Y, Zheng Z, Ran W, Zhai Y, Yin Q, Zhang P, Li Y	Cocktail Strategy Based on Spatio-Temporally Controlled Nano Device Improves Therapy of Breast Cancer.	Advanced materials (Deerfield Beach, Fla.)	doi: 10.1002/adma.201806202
30515783	2018 Dec 4	Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S	Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.	International journal of cancer	doi: 10.1002/ijc.32041
30515719	2018 Dec 4	Huang M, Pietanza MC, Samkari A, Pellissier J, Burke T, Chandwani S, Kong F, Pickard AS	Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.	PharmacoEconomics	doi: 10.1007/s40273-018-0752-0
30515672	2018 Dec 4	Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Watanabe M	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	doi: 10.1007/s10120-018-0903-1
30514902	2018 Dec 4	Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y, Hung MC	Palmitoylation stabilizes PD-L1 to promote breast tumor growth.	Cell research	doi: 10.1038/s41422-018-0124-5
